Skip to content

A comparative study of the short and long-term efficacy of early Siewert II/III esophagogastric junction carcinoma of proximal gastrectomy (SOFY anastomosis) versus total gastrectomy

A comparative study of the short and long-term efficacy of early Siewert II/III esophagogastric junction carcinoma of proximal gastrectomy (SOFY anastomosis) versus total gastrectomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042220
Enrollment
Unknown
Registered
2021-01-16
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Experimental group:Proximal gastrectomy (SOFY anastomosis)
Control group:Total gastrectomy (Roux-en-Y anastomosis)

Sponsors

Beijing Friendship Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with Siewert II/III esophagogastric junction carcinoma diagnosed by endoscopy and pathology had complete clinical stage diagnosis before operation, including abdominal enhanced CT and / or gastroscopy. The clinical pathological stage was cT1N0M0; 2. Subjects aged 18-75 years old (including 18-75 years old), regardless of gender; 3. Physical strength score: ECoG 100 x 10^9 / L); 6. The subjects who can understand and abide by the research protocol agree and sign the informed consent form; 7. Subjects with relatively complete case data and follow-up data.

Exclusion criteria

Exclusion criteria: 1. Subjects contraindicated by gastroscopy; 2. Patients with blood coagulation dysfunction, cardiopulmonary dysfunction and other surgical contraindications, or patients with uncontrolled epilepsy, central nervous system diseases or mental disorders, or patients with organ transplantation requiring immunosuppressive therapy; 3. Subjects who failed to accept standard D2 radical gastrectomy for gastric cancer; 4. During pregnancy and lactation, those who may not take effective contraceptive measures and those who are going to get pregnant; 5. Patients with gastric cancer or other related diseases; 6. Subjects receiving preoperative radiotherapy or chemotherapy; 7. Subjects with other organ resection (liver, pancreas, spleen, colon); 8. Participants in other clinical trials at the same time.

Design outcomes

Primary

MeasureTime frame
reflux rate;

Countries

China

Contacts

Public ContactYin Jie

Beijing Friendship Hospital Affiliated to Capital Medical University

yj232325@sina.com+86 15011302788

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026